Nuvectis Pharma, Inc. (NVCT)

Nuvectis Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	17.17	19.13	19.99	5.74	-
Cash & Short-Term Investments	17.17	19.13	19.99	5.74	-
Cash Growth	-22.17%	-4.34%	248.19%	-	-
Other Current Assets	0.14	0.06	0.41	0.09	-
Total Current Assets	17.31	19.19	20.41	5.83	-
Long-Term Deferred Charges	-	-	-	0.82	-
Total Assets	17.31	19.19	20.41	6.66	-
Accounts Payable	2.26	2.77	2.91	1.06	0.01
Accrued Expenses	4.06	4.21	2.83	0.54	-
Other Current Liabilities	-	-	0.45	0.82	-
Total Current Liabilities	6.32	6.98	6.19	2.42	0.01
Total Liabilities	6.32	6.98	6.19	2.42	0.01
Additional Paid-In Capital	77.99	66.45	46.2	1.89	-
Retained Earnings	-67	-54.25	-31.99	-12.9	-0.01
Total Common Equity	10.99	12.2	14.22	-11.01	-0.01
Shareholders' Equity	10.99	12.2	14.22	4.24	-0.01
Total Liabilities & Equity	17.31	19.19	20.41	6.66	-
Net Cash (Debt)	17.17	19.13	19.99	5.74	-
Net Cash Growth	-22.17%	-4.34%	248.19%	-	-
Net Cash Per Share	1.03	1.23	1.58	1.35	-
Filing Date Shares Outstanding	19.32	17.77	14.75	12.72	3.9
Total Common Shares Outstanding	18.99	17.42	14.64	4.51	3.9
Working Capital	10.99	12.2	14.22	3.41	-0.01
Book Value Per Share	0.58	0.70	0.97	-2.44	-0.00
Tangible Book Value	10.99	12.2	14.22	-11.01	-0.01
Tangible Book Value Per Share	0.58	0.70	0.97	-2.44	-0.00

Source: S&P Capital IQ. Standard template. Financial Sources.